INS NYC 2024 Program

Custom Content

Poster Session 06 Program Schedule

02/15/2024
04:00 pm - 05:15 pm
Room: Shubert Complex (Posters 1-60)

Poster Session 06: Aging | MCI | Neurodegenerative Disease - PART 2


Final Abstract #16

Poster Symposium: The Black American Neurodegenerative Discovery (BAND)- Together Initiative: Project Methods and Collaborator Perspectives for Launching Community-Engaged Research — Abstract 5

The BAND-Together Initiative: Perspective of a Clinician Collaborator

Malgorzata Franczak, Medical College of Wisconsin, Milwaukee, United States
Benjamin Tobin, Froedtert Hospital, Milwaukee, United States

Category: Inclusion and Diversity/Multiculturalism

Keyword 1: diversity
Keyword 2: inclusion
Keyword 3: dementia - Alzheimer's disease

Objective:

Alzheimer’s disease (AD) is the most common neurodegenerative dementia and disproportionately affects African Americans and other racial and ethnic minority groups. The rates of dementia diagnosis, use of approved AD treatments, and survival rates are all lower among African Americans than any other racial or ethnic groups. Older Black American adults also present with an earlier age of onset than Whites, are more likely to present with chronic comorbidities (e.g., diabetes and high blood pressure), show greater symptom severity at the time of presentation to clinics, and are more likely to receive an AD diagnosis at later stages; resulting in less treatment and planning options, along with higher caregiver burden and increased health care costs. As a physician and BAND-Together co-investigator, there is clear value in building lasting bidirectional relationships between doctors and community members to work toward early identification and intervention in African Americans. Reducing disparities in clinical trials is also critical, especially to ensure that new treatments are safe and efficacious in minoritized groups. This presentation will cover 1) barriers to AD and related dementias (ADRD) care and research participation, with a particular focus FDA-approved anti-amyloid therapies and clinical trials research, 2) initial steps taken to make the BAND-Together initiative possible and the power of trust, education, and partnership to reduce ADRD health disparities and improve the science of inclusion.

Participants and Methods:

not applicable

Results:

not applicable

Conclusions:

not applicable